London & New York, Sept. 15, 2025 (GLOBE NEWSWIRE) -- OPEN Health, a global leader in medical affairs, health economics and outcomes research (HEOR) and market access, patient engagement, and consulting services, today announced that its near-term and net-zero emission reduction targets have been officially validated by the Science Based Targets initiative (SBTi).
This milestone affirms that OPEN Health's environmental ambitions are in line with the SBTi Net-Zero Standard and the latest climate science of limiting global warming to 1.5°C above pre-industrial levels by 2050.
Matt D'Auria, Chief Executive Officer of OPEN Health, commented:
“Validation of our science-based targets marks a vital step forward in our commitment to protecting the planet. This milestone strengthens our resolve and paves the way for deeper collaboration with partners to create a more sustainable future.”
The SBTi sets the industry standard for corporate emission reduction targets and strategies, and OPEN Health is proud to share our validated targets.
Near term (2030)
- Reduce Scope 1 and 2 emissions by 42% by 2030 from a 2023 baseline.
- Reduce Scope 3 emissions by 25% by 2030 from a 2023 baseline.
Net Zero (2050)
- Reduce Scope 1, 2, and 3 emissions by 90% and neutralize any residual emissions to achieve net zero by 2050.
In conjunction with these targets, OPEN Health has outlined a reduction strategy to annually measure and address each scope of emissions. For more information on our emission reduction progress and sustainability strategy, visit our website or read our 2024 IMPACT Report.
By securing this validation, OPEN Health underscores its commitment to transparency, accountability, and meaningful climate action.
About SBTi
The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. SBTi develops standards, tools, and guidance that allow companies to set targets for reductions in greenhouse gas emissions in line with what is needed to keep global heating below catastrophic levels and reach net zero by 2050 at the latest.
SBTi partners with CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the Worldwide Fund for Nature (WWF).
More information can be found here: https://sciencebasedtargets.org
About OPEN Health
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact. By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
OPEN Health. The right combination to unlock possibilities.
To learn more, visit www.openhealthgroup.com
Contact:
Candice Subero
OPEN Health
candicesubero@openhealthgroup.com
-
SuperX与中恒电气成立合资公司,以颠覆性供电技术重塑全球AI数据中心能源格局新成立的合资公司“SuperX Digital Power”将整合双方优势,面向全球(除中国大陆、香港、澳门外)市场推出的高压直流(HVDC)解决方案,直击AI 算力高能耗痛点,提供更高效率2025-09-15
-
圣莱科特国际集团将亮相K 2025行业领军者发布塑料与橡胶领域先进解决方案 德克萨斯州伍德兰兹2025年9月15日 美通社 -- 在德国杜塞尔多夫于2025年10月8日至15日举行的K 2025展览会期间,全球领先2025-09-15
-
展望 “健康中国2030” ,Eurofins Central Lab助力临床试验出海,加速中国生物医药全球化苏州2025年9月15日 美通社 -- 2025年苏州OCT会议近日圆满落幕,本次会议聚焦中国生物医药行业的迅猛发展与全球化进程。多位行业领袖、政策专家与企业代表齐聚一堂,共2025-09-15
-
韩国演员李恩知与携手bnt拍摄写真 回顾成长历程畅谈未来目标近日,“Mano Family”代表——恩知姐姐(本名李恩知)与韩国bnt娱乐携手完成了一组全新写真拍摄。活跃于中韩两地的她,一直致力于搭建两国网红交流的桥梁。此次,她罕见2025-09-15
-
大睿生物宣布RN3161澳洲临床试验申请获受理差异化INHBE siRNA进入临床,开启肥胖治疗新格局 上海和加利福尼亚州圣巴巴拉2025年9月15日 美通社 -- 专注于开发下一代RNAi疗法的全球化生物医药公司大睿生物(Rona2025-09-15